A novel Cdk9 inhibitor preferentially targets tumor cells and synergizes with fludarabine - Wikidata - wikimedia - TriplyDB

A novel Cdk9 inhibitor preferentially targets tumor cells and synergizes with fludarabine

A novel Cdk9 inhibitor preferentially targets tumor cells and synergizes with fludarabine

http://www.wikidata.org/entity/Q38457498

about

Targeting cyclin-dependent kinases in human cancers: from small molecules to Peptide inhibitors Tumor suppressor XAF1 induces apoptosis, inhibits angiogenesis and inhibits tumor growth in hepatocellular carcinoma.Targeting RNA transcription and translation in ovarian cancer cells with pharmacological inhibitor CDKI-73.The history and future of targeting cyclin-dependent kinases in cancer therapy.The p53 transcriptional pathway is preserved in ATMmutated and NOTCH1mutated chronic lymphocytic leukemias.Targeting cell cycle regulators in hematologic malignancies.Cyclin-Dependent Kinase Inhibitor P1446A Induces Apoptosis in a JNK/p38 MAPK-Dependent Manner in Chronic Lymphocytic Leukemia B-Cells.Bay 61-3606 Sensitizes TRAIL-Induced Apoptosis by Downregulating Mcl-1 in Breast Cancer Cells.Cyclin-dependent kinase inhibitor dinaciclib potently synergizes with cisplatin in preclinical models of ovarian cancer.CDK9 inhibitors selectively target estrogen receptor-positive breast cancer cells through combined inhibition of MYB and MCL-1 expression.Dual inhibition of Mcl-1 by the combination of carfilzomib and TG02 in multiple myeloma.Antitumor action of CDK inhibitor LS-007 as a single agent and in combination with ABT-199 against human acute leukemia cells.Inhibition of cyclin dependent kinase 9 by dinaciclib suppresses cyclin B1 expression and tumor growth in triple negative breast cancer Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Cyclin-dependent kinase 9 is required for the survival of adult Drosophila melanogaster glia.Overview of CDK9 as a target in cancer research.Targeting Cyclin-Dependent Kinases in Ovarian Cancer.Recent progress of cyclin-dependent kinase inhibitors as potential anticancer agents.Inhibitors of cyclin-dependent kinases as cancer therapeutics.Systematic Kinase Inhibitor Profiling Identifies CDK9 as a Synthetic Lethal Target in NUT Midline Carcinoma.Cellular pharmacology studies of anticancer agents: recommendations from the EORTC-PAMM group.CDK9 inhibitors in acute myeloid leukemia.Molecular principle of the cyclin-dependent kinase selectivity of 4-(thiazol-5-yl)-2-(phenylamino) pyrimidine-5-carbonitrile derivatives revealed by molecular modeling studies.Potent anti-leukemic activity of a specific cyclin-dependent kinase 9 inhibitor in mouse models of chronic lymphocytic leukemia.Transcriptional targeting of oncogene addiction in medullary thyroid cancer

P2860

Q26827580-9F423784-BCB4-4979-9837-8AAAF9338CF7 Q34221867-18C5B0C0-7B75-49F4-853D-3429C0CB9E32 Q34365839-A1C8EED9-3021-4E66-9360-196B26985CBD Q34460347-743DC86E-04F0-493C-A0D1-A05814708ADF Q35149661-64448A05-C4AC-4755-A724-314388CBAF35 Q35334436-7A8FB865-D15E-4680-A999-F1959281A3A5 Q35852684-96B4DFE7-2B0C-49FA-BFEB-31311B77A68F Q35882493-0A1284E9-DE9E-46B0-8EBB-DD55ED226EE4 Q36020882-83E33473-AA26-4082-9BD9-8A2E51F73619 Q36962507-4C9A1C75-FDA8-4BDB-BD74-0FD72030D55B Q37146291-13D46EBC-A843-407A-AEDE-FD2598D12938 Q37399378-E101182B-726B-418D-A180-77833444F5A3 Q37636710-2E62FA77-2687-4867-96FA-D82D8C401B13 Q38544813-F71FC5D3-08CA-4D15-86B8-099BC2228A43 Q38654269-18D56225-4937-407C-AB63-71898FAB58D3 Q38696353-41D524F0-22C1-4C72-961C-AE6F0EB4010F Q38730812-BC03E0F5-256E-4349-9850-B784868BA857 Q38806786-8C478B18-731D-4C2E-8FD3-5619089BCE0E Q39125016-8E8D8D2B-87AB-47F0-8315-8A8A28374295 Q42367759-FA17A857-1717-468E-93E5-49FB203EB045 Q49504547-07B5D832-06AC-4EA3-9469-74681A327BE1 Q50318294-8E14457A-8846-42B2-8CA9-0A2E9B4E7318 Q55033883-BDDBE599-169B-4B98-9DC5-1569D52254C8 Q55280895-C6D20988-CB8D-4223-9F49-2DB415724B54 Q58710816-B0B2EE99-A594-4D2E-B4B0-71725512AEDF

P2860

A novel Cdk9 inhibitor preferentially targets tumor cells and synergizes with fludarabine

http://www.wikidata.org/entity/Q38457498

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

A novel Cdk9 inhibitor preferentially targets tumor cells and synergizes with fludarabine

@en

type

label

A novel Cdk9 inhibitor preferentially targets tumor cells and synergizes with fludarabine

@en

prefLabel

A novel Cdk9 inhibitor preferentially targets tumor cells and synergizes with fludarabine

@en

P1433

Q38457498-050D32B2-5FCE-4ED0-97A5-9AB52C28AA50

P1476

Q38457498-16263929-CFE3-47F5-82C7-90DF58BE428E

P2093

Q38457498-0F7E3C3D-6FD9-4557-9523-3D9DC08F255D

Q38457498-523DD22F-9E56-421B-8EBF-CCC957FD4838

Q38457498-5839E870-936F-4B33-89EB-2BFAFCA63D63

Q38457498-7A9EA6CC-C76F-4DEA-A33C-27404D92EC38

Q38457498-82A90B29-121B-4529-BA88-C92838201296

Q38457498-A84E5F54-01FE-4134-9B50-1BBEB72951E1

Q38457498-D0618B70-D72F-4934-9B5D-989D89099277

Q38457498-DA3549BE-181D-47C2-B2A7-73ADD1DCE291

Q38457498-F0AA91FE-E646-4541-BB45-4006029E14E5

P2860

Q38457498-013580DE-1468-410F-875B-8F1EC5903DFC

Q38457498-08CDC14A-98BF-4C64-BBCF-7B2DA94B58EA

Q38457498-0D90CA69-4204-4110-8EBC-998CE7E65011

Q38457498-11900C9D-978B-44D4-A541-3FC96869B094

Q38457498-132B5B32-E456-4CE8-8682-CA53D14EC21D

Q38457498-140DF9D8-1D2F-4583-A688-6979C02F8F57

Q38457498-1470B78F-5B73-42E6-A311-799942891F39

Q38457498-174C56EF-22DB-42E3-A96A-6D77EF060BA2

Q38457498-249B973F-4315-429D-910A-85AD9A053000

Q38457498-2628E633-5CAE-48F0-ACC4-E4B4DFE3F2C0

P304

Q38457498-141C3FE5-375B-4241-96D4-8AC7007BA0BB

P31

Q38457498-8ACD29B9-0D97-4C06-93CD-2EF036BF4621

P356

Q38457498-6412CF13-F2C7-42EE-947B-18978BA5D439

P407

Q38457498-1AB73A41-4EC9-4BD2-BA33-65B2782E3482

P433

Q38457498-274FC920-750F-4606-850C-B38162DD9A42

P478

Q38457498-CF544BA0-A0AB-4108-99BD-02B3E6DC5548

P50

Q38457498-4149BD11-DD78-40DA-9F10-CABC78BBDC04

P577

Q38457498-5DC86499-9566-4924-8068-F5C2FB08E5F1

P698

Q38457498-0AD765C8-7EE8-4F79-8C42-69D714161A67

P932

Q38457498-7D711ABF-254B-458C-B474-58237383492A

P356

ONCOTARGET.1568

P1433

P1476

A novel Cdk9 inhibitor preferentially targets tumor cells and synergizes with fludarabine

@en

P2093

Abdullah Y Abbas

http://www.w3.org/2001/XMLSchema#string

Chris Fegan

http://www.w3.org/2001/XMLSchema#string

Chris Pepper

http://www.w3.org/2001/XMLSchema#string

Elisabeth Walsby

http://www.w3.org/2001/XMLSchema#string

Guy Pratt

http://www.w3.org/2001/XMLSchema#string

Hao Shao

http://www.w3.org/2001/XMLSchema#string

Peter M Fischer

http://www.w3.org/2001/XMLSchema#string

Shudong Wang

http://www.w3.org/2001/XMLSchema#string

Tracey D Bradshaw

http://www.w3.org/2001/XMLSchema#string

P2860

Discovery and characterization of 2-anilino-4- (thiazol-5-yl)pyrimidine transcriptional CDK inhibitors as anticancer agents

The CDK9 Tail Determines the Reaction Pathway of Positive Transcription Elongation Factor b

Substituted 4-(Thiazol-5-yl)-2-(phenylamino)pyrimidines Are Highly Active CDK9 Inhibitors: Synthesis, X-ray Crystal Structures, Structure–Activity Relationship, and Anticancer Activities

Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1

Cyclin-dependent kinase pathways as targets for cancer treatment

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

Development of cyclin-dependent kinase modulators as novel therapeutic approaches for hematological malignancies.

Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805.

In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.

P304

375-385

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.1568

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24495868

http://www.w3.org/2001/XMLSchema#string

P932

3964214

http://www.w3.org/2001/XMLSchema#string